Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”
Stevanato Group (NYSE: STVN), Gerresheimer AG (MDAX: GXI), and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP) have formed the 'Alliance for RTU' to promote the adoption of Ready-to-Use (RTU) vials and cartridges in the pharmaceutical industry. This strategic alliance aims to share expertise on high-quality sterile primary packaging with pharmaceutical companies, CMOs, and CDMOs.
The alliance highlights the advantages of RTU configurations over conventional bulk packaging, including reduced operational risks, enhanced flexibility, increased efficiency, and lower total cost of ownership. RTU technology can help streamline processes, increase productivity, and reduce contamination risks while easing EU GMP Annex 1 compliance.
The Alliance for RTU will create an open expert platform to help industry manufacturers learn about the benefits of RTU processes and products, supporting the transition to efficient filling systems for both clinical applications and commercial use.
Stevanato Group (NYSE: STVN), Gerresheimer AG (MDAX: GXI) e SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP) hanno formato l''Alleanza per il RTU' per promuovere l'adozione di fiale e cartucce pronte all'uso (RTU) nell'industria farmaceutica. Questa alleanza strategica mira a condividere competenze sulla produzione di imballaggi primari sterili di alta qualità con le aziende farmaceutiche, i CMO e i CDMO.
L'alleanza sottolinea i vantaggi delle configurazioni RTU rispetto all'imballaggio convenzionale in bulk, tra cui rischi operativi ridotti, maggiore flessibilità, efficienza aumentata e minor costo totale di proprietà. La tecnologia RTU può contribuire a semplificare i processi, aumentare la produttività e ridurre i rischi di contaminazione, facilitando al contempo la conformità all'Allegato 1 delle GMP europee.
L'Alleanza per il RTU creerà una piattaforma esperta aperta per aiutare i produttori del settore a conoscere i vantaggi dei processi e dei prodotti RTU, sostenendo la transizione a sistemi di riempimento efficienti per applicazioni cliniche e uso commerciale.
Stevanato Group (NYSE: STVN), Gerresheimer AG (MDAX: GXI) y SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP) han formado la 'Alianza por el RTU' para promover la adopción de viales y cartuchos listos para usar (RTU) en la industria farmacéutica. Esta alianza estratégica tiene como objetivo compartir experiencia sobre envases primarios estériles de alta calidad con empresas farmacéuticas, CMO y CDMO.
La alianza destaca las ventajas de las configuraciones RTU en comparación con el embalaje convencional a granel, incluyendo riesgos operativos reducidos, mayor flexibilidad, eficiencia aumentada y menor costo total de propiedad. La tecnología RTU puede ayudar a agilizar procesos, aumentar la productividad y reducir los riesgos de contaminación, facilitando al mismo tiempo el cumplimiento del Anexo 1 de las GMP de la UE.
La Alianza por el RTU creará una plataforma experta abierta para ayudar a los fabricantes de la industria a aprender sobre los beneficios de los procesos y productos RTU, apoyando la transición a sistemas de llenado eficientes tanto para aplicaciones clínicas como para uso comercial.
Stevanato Group (NYSE: STVN), Gerresheimer AG (MDAX: GXI), 그리고 SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP)는 제약 산업에서 사용하기 위한 준비가 완료된(RTU) 바이알 및 카트리지의 채택을 촉진하기 위해 'RTU를 위한 동맹'을 결성했습니다. 이 전략적 동맹은 제약 회사, CMO 및 CDMO와 함께 고품질의 멸균 기본 포장에 대한 전문 지식을 공유하는 것을 목표로 합니다.
이 동맹은 전통적인 벌크 포장에 비해 RTU 구성의 장점을 강조하며, 작업 리스크 감소, 유연성 향상, 효율성 증가 및 총 소유비용 절감 등을 포함합니다. RTU 기술은 프로세스를 간소화하고 생산성을 높이며 오염 위험을 줄이고 유럽 GMP 부칙 1 준수를 용이하게 할 수 있습니다.
RTU를 위한 동맹은 산업 제조업체가 RTU 프로세스 및 제품의 이점을 배울 수 있도록 돕는 개방형 전문 플랫폼을 생성하여 임상 응용과 상업적 사용 모두를 위한 효율적인 충전 시스템으로의 전환을 지원할 것입니다.
Stevanato Group (NYSE: STVN), Gerresheimer AG (MDAX: GXI) et SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP) ont formé l''Alliance pour le RTU' pour promouvoir l'adoption de flacons et de cartouches prêts à l'emploi (RTU) dans l'industrie pharmaceutique. Cette alliance stratégique vise à partager son expertise sur l'emballage primaire stérile de haute qualité avec des entreprises pharmaceutiques, des CMO et des CDMO.
L'alliance met en avant les avantages des configurations RTU par rapport à l'emballage en vrac classique, y compris réduction des risques opérationnels, flexibilité accrue, efficacité augmentée et coût total de possession réduit. La technologie RTU peut aider à rationaliser les processus, augmenter la productivité et réduire les risques de contamination tout en facilitant la conformité avec l'Annexe 1 des GMP de l'UE.
L'Alliance pour le RTU créera une plateforme d'experts ouverte pour aider les fabricants de l'industrie à découvrir les avantages des processus et produits RTU, soutenant la transition vers des systèmes de remplissage efficaces pour les applications cliniques et l'utilisation commerciale.
Die Stevanato Group (NYSE: STVN), die Gerresheimer AG (MDAX: GXI) und die SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP) haben die 'Allianz für RTU' gegründet, um die Adoption von gebrauchsfertigen (RTU) Vials und Kartuschen in der Pharmaindustrie zu fördern. Diese strategische Allianz hat das Ziel, Fachwissen über hochwertige sterile Primärverpackungen mit pharmazeutischen Unternehmen, CMO und CDMO zu teilen.
Die Allianz hebt die Vorteile von RTU-Konfigurationen gegenüber herkömmlicher Bulkverpackung hervor, einschließlich geringerer operationeller Risiken, erhöhter Flexibilität, gesteigerter Effizienz und niedrigeren Gesamtkosten des Eigentums. Die RTU-Technologie kann helfen, Prozesse zu straffen, die Produktivität zu erhöhen und Kontaminationsrisiken zu mindern, während sie gleichzeitig die Einhaltung des Anhangs 1 der EU GMP erleichtert.
Die Allianz für RTU wird eine offene Expertenplattform schaffen, um Herstellern der Branche zu helfen, die Vorteile von RTU-Prozessen und -Produkten kennenzulernen und den Übergang zu effizienten Abfüllsystemen für klinische Anwendungen und kommerzielle Nutzung zu unterstützen.
- Formation of strategic 'Alliance for RTU' to promote adoption of Ready-to-Use vials and cartridges
- Potential for reduced operational risks and lower total cost of ownership for pharmaceutical companies
- Improved efficiency and productivity in pharmaceutical manufacturing processes
- Enhanced product quality and reduced contamination risks
- Creation of an open expert platform to support industry transition to RTU solutions
- None.
Insights
The formation of the "Alliance for RTU" between Stevanato Group, Gerresheimer and SCHOTT Pharma is a significant development in the pharmaceutical packaging industry. This strategic alliance aims to promote the adoption of Ready-to-Use (RTU) vials and cartridges, which could have far-reaching implications for pharmaceutical manufacturing processes.
Key points to consider:
- The alliance targets increased operational efficiency and patient safety in pharmaceutical manufacturing.
- RTU containers offer reduced risks, lower total cost of ownership and improved compliance with EU GMP Annex 1.
- The move reflects a broader industry trend towards advanced aseptic filling technologies, driven by growing demand for injectable medicines and stricter safety regulations.
- This collaboration among major players could accelerate the transition from traditional bulk packaging to RTU solutions, potentially reshaping industry standards.
While the immediate financial impact may be , the long-term implications for these companies and the broader pharmaceutical supply chain could be substantial. Investors should monitor how this alliance influences market adoption rates of RTU technologies and the potential for increased market share for the participating companies.
The "Alliance for RTU" represents a pivotal shift in pharmaceutical manufacturing, addressing critical challenges in the industry. RTU vials and cartridges offer several advantages over conventional bulk packaging:
- Enhanced sterility and reduced contamination risks, important for compliance with stringent regulations like EU GMP Annex 1
- Improved operational efficiency, potentially leading to significant cost savings for pharmaceutical companies and CMOs
- Higher quality products with minimized glass particle release and reduced breakage risks
- Increased flexibility in production processes, particularly beneficial for smaller batch sizes and personalized medicines
This alliance, bringing together three major players in pharmaceutical packaging, signals a strong industry commitment to RTU technology. It could accelerate the adoption of these advanced solutions, particularly among smaller pharmaceutical companies and CMOs who might have been hesitant due to perceived complexities or costs. The initiative to create an open expert platform for RTU industry standards is particularly noteworthy, as it could lead to wider acceptance and potentially new innovations in the field.
- Market advances adoption of ready-to-use containers
- Improved operational efficiency in pharmaceutical manufacturing processes
- Increased patient safety with high-quality sterile primary packaging
PIOMBINO DESE,
Stevanato Group, Gerresheimer & SCHOTT Pharma join forces in the 'Alliance for RTU' (Photo: Business Wire)
The Alliance for RTU aims to share with pharmaceutical companies, CMOs and CDMOs expertise and technical knowledge in high-quality sterile primary packaging, specifically ready-to-fill vials and cartridges, highlighting RTU configurations' advantages over conventional bulk packaging.
Reduced risks and lower total cost of ownership
Traditional fill&finish processes present several operational risks and require increased efficiency. By adopting an industrial ready-to-use (RTU) setup, pharmaceutical companies and Contract Manufacturing Organizations (CMOs) can benefit from reduced operational risks, enhanced flexibility and efficiency, and lower waste. RTU technology can help streamline processes, increase productivity, and thus lower total cost of ownership (TCO) while reducing contamination risks and easing EU GMP Annex 1 compliance.
Pharmaceutical companies, CMOs and CDMOs opting for ready-to-use containers also can benefit from higher-quality products, which helps minimize the release of glass particles and risks of breakage or rejection while preserving the drug inside throughout its entire life cycle.
Open expert platform for RTU industry standard
Additionally, the market is driving investment in advanced aseptic filling technologies due to increasing demand for injectable medicines and regulatory pressure to meet safety standards. In this context, the Alliance for RTU aims to create an expert platform open to other industry players to help industry manufacturers learn about the key benefits of RTU processes and products and to better evaluate investments for transitioning to efficient filling systems and meeting their unique needs from clinical applications to widespread commercial use.
“RTU vials and cartridges represent a significant advancement in product quality, offering enhanced reliability and efficiency in pharmaceutical processes. This alliance allows us to highlight further how RTU solutions elevate standards across the industry, ensuring safer and more effective delivery of medications to patients worldwide," said Franco Stevanato, CEO at Stevanato Group.
“The shift towards ready-to-use vials and cartridges reflects a collective industry move to advance quality and efficiency in aseptic filling processes and this alliance shows readiness by expanding capacity and thereby supporting this market trend,” said Andreas Reisse, CEO at SCHOTT Pharma. “Ready-to-use solutions can reduce complexities and better meet the stringent requirements of modern pharmaceutical production.”
"As an industry, we are fully prepared for the transition to RTU vials and cartridges”, said Lukas Burkhardt, Member of the Management Board of Gerresheimer AG. “With recent advancements, RTU processing is now a mature technology which will improve our customers operations in terms of efficiency, cost and time to market."
The Alliance for RTU will be officially presented at the CPHI in
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner to the pharma, biotech, and cosmetics industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper and syrup bottles, and more. With 35 production sites in 16 countries in
About SCHOTT Pharma
Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in
Forward-Looking Statements
This press release may include forward-looking statements. The words “aims”, “”increase”, “lower”, “ is driving”, “increasing”, “create”, “move”, “expanding”, “advance”, “can”, “will”, and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240926050295/en/
Media Stevanato Group
media@stevanatogroup.com
Cassie Gonzalez: stevanatoUS@teamlewis.com
Investor Relations Stevanato Group
Lisa Miles: lisa.miles@stevanatogroup.com
Media Gerresheimer AG
Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264
jutta.lorberg@gerresheimer.com
Investor Relations Gerresheimer AG
Guido Pickert
Vice President Investor Relations
T +49 152 900 14145
gerresheimer.ir@gerresheimer.com
Media SCHOTT Pharma
Joana Kornblum
Tel.: +49 151/29223552
E-Mail: joana.kornblum@schott.com
Investor Relations SCHOTT Pharma
Jasko Terzic, CFA
E-Mail: ir.pharma@schott.com
Source: Stevanato Group
FAQ
What is the 'Alliance for RTU' announced by Stevanato Group (STVN)?
What are the benefits of RTU vials and cartridges according to the Stevanato Group (STVN) announcement?
How will the 'Alliance for RTU' support pharmaceutical companies according to Stevanato Group (STVN)?
When and where will the 'Alliance for RTU' be officially presented by Stevanato Group (STVN)?
